ALACHUA, Fla., Aug. 24, 2017 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in the 72nd Annual Meeting of the American Society for Surgery of the Hand (ASSH). The meeting, scheduled for September 7-9 at the Moscone West Convention Center in San Francisco, is the largest international gathering of hand surgeons and features scientific sessions, training opportunities, poster presentations, and exhibits.
AxoGen is a premier partner for the meeting and will host a breakfast symposium and panel discussion on September 8 at 7:00 a.m. The symposium, Current Concepts in the Surgical Treatment of Mixed and Motor Nerve Injuries, will include a discussion with three of the country’s leading hand surgeons. The case-based discussion will demonstrate key principles on rapidly evolving algorithms and techniques, discuss the growing body of published clinical evidence on mixed, motor, and long-gap nerve repairs, and allow participants to collaborate on surgical treatment plans to address challenging patient scenarios.
In addition to the symposium, AxoGen will sponsor several special events that support peripheral nerve education and awareness, including a Hand Fellows pre-course and the Women in Hand Surgery thought leaders’ reception. AxoGen’s comprehensive nerve repair platform will be featured at Booth #819. Surgeons visiting the AxoGen booth will have the opportunity to practice microsurgery suturing and handling techniques at a specially equipped station.
“We welcome the opportunity to partner with ASSH in bringing clinically proven peripheral nerve repair solutions to its members through surgeon-led educational symposia,” said Karen Zaderej, president and chief executive officer. “The annual ASSH meeting provides a scientific venue for us to talk with our hand surgeon customers about how they are using our product platform to improve surgical outcomes for their patients with peripheral nerve injuries.”
AxoGen also partners with ASSH by providing support for society programs such as Touching Hands, a mission trip to treat patients in underprivileged regions; grants for society-sponsored peripheral nerve research; and grants to support conference attendance and training for residents, fellows, and military personnel.
About ASSH
The American Society for Surgery of the Hand is the oldest medical society dedicated to the hand and upper extremity. Its mission is to advance the science and practice of hand and upper extremity surgery through education, research, and advocacy on behalf of patients and practitioners. For more information, please visit www.assh.org.
About AxoGen
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen is the only company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact: AxoGen Corporation Annette Ruzicka Corporate and Investor Communications 763-458-4193 aruzicka@axogeninc.com
